Healthcare provider profile · identity verified

Hector M. Cabrera, M.D.

Allopathic & Osteopathic Physicians|Family Medicine · NEW ORLEANS, LA · NPI 1922007012

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Hector M. Cabrera, M.D. received $27.76 in general payments during 2025 across 2 reported records.

AstraZeneca Pharmaceuticals LP accounted for 50.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Paxlovid.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lokelma by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 630 claims for Eliquis by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$27.76

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$13.95	50.2%	1	2025
PFIZER INC.	Unresolved — no canonical attribution shown	$13.81	49.8%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$27.76	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$13.95	1	2025
Source payment records 2025-12-11 · AstraZeneca Pharmaceuticals LP · $13.95 · Open Payments source
NURTEC ODT Normalized: nurtec odt	Drug	PFIZER INC.	$13.81	1	2025
Source payment records 2025-12-11 · PFIZER INC. · $13.81 · Open Payments source
PAXLOVID Normalized: paxlovid	Drug	PFIZER INC.	$13.81	1	2025
Source payment records 2025-12-11 · PFIZER INC. · $13.81 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	15 Beneficiary count suppressed	exact normalized	Medicare Part D
PAXLOVID paxlovid	2025	Paxlovid	2024	35	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	22	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	LOKELMA open payments reported associated product	CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624	Lokelma · 2024 Exact normalized brand match · 1 Part D row	17	suppressed by CMS
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	630	69
PFIZER INC. Exact reporting entity; no affiliate inference	2025	PAXLOVID open payments reported associated product	CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432	Paxlovid · 2024 Exact normalized brand match · 1 Part D row	35	35

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1034	136
Amlodipine Besylate	Amlodipine Besylate	806	111
Levothyroxine Sodium	Levothyroxine Sodium	734	82
Eliquis	Apixaban	630	69
Donepezil Hcl	Donepezil Hcl	567	56
Furosemide	Furosemide	537	76
Pantoprazole Sodium	Pantoprazole Sodium	479	76
Memantine Hcl	Memantine Hcl	434	56
Gabapentin	Gabapentin	409	50
Mirtazapine	Mirtazapine	377	57
Potassium Chloride	Potassium Chloride	373	58
Lisinopril	Lisinopril	369	46
Metoprolol Succinate	Metoprolol Succinate	356	49
Sertraline Hcl	Sertraline Hcl	320	34
Losartan Potassium	Losartan Potassium	312	43
Escitalopram Oxalate	Escitalopram Oxalate	303	41
Levetiracetam	Levetiracetam	269	31
Quetiapine Fumarate	Quetiapine Fumarate	231	28
Hydralazine Hcl	Hydralazine Hcl	226	32
Carvedilol	Carvedilol	222	38
Trazodone Hcl	Trazodone Hcl	213	31
Clopidogrel	Clopidogrel Bisulfate	208	24
Omeprazole	Omeprazole	194	25
Januvia	Sitagliptin Phosphate	190	16
Rosuvastatin Calcium	Rosuvastatin Calcium	190	27
Metformin Hcl	Metformin Hcl	184	28
Fluticasone Propionate	Fluticasone Propionate	182	62
Buspirone Hcl	Buspirone Hcl	176	20
Latanoprost	Latanoprost	171	27
Prednisone	Prednisone	163	102
Meloxicam	Meloxicam	160	36
Tamsulosin Hcl	Tamsulosin Hcl	145	36
Pravastatin Sodium	Pravastatin Sodium	139	13
Famotidine	Famotidine	138	28
Carbidopa-Levodopa	Carbidopa/Levodopa	129	15
Duloxetine Hcl	Duloxetine Hcl	123	18
Metoprolol Tartrate	Metoprolol Tartrate	118	26
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	116	23
Allopurinol	Allopurinol	113	14
Bumetanide	Bumetanide	113	19
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	111	30
Citalopram Hbr	Citalopram Hydrobromide	110	13
Fluoxetine Hcl	Fluoxetine Hcl	110	16
Finasteride	Finasteride	109	11
Alendronate Sodium	Alendronate Sodium	108	17
Spironolactone	Spironolactone	105	17
Triamcinolone Acetonide	Triamcinolone Acetonide	100	39
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	99	25
Albuterol Sulfate	Albuterol Sulfate	98	38
Myrbetriq	Mirabegron	98	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	92	12
Novolog Flexpen	Insulin Aspart	91	17
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	90	79
Xarelto	Rivaroxaban	88	suppressed
Clonidine Hcl	Clonidine Hcl	85	13
Cephalexin	Cephalexin	84	48
Ezetimibe	Ezetimibe	84	12
Oxybutynin Chloride	Oxybutynin Chloride	84	suppressed
Jardiance	Empagliflozin	80	11
Divalproex Sodium	Divalproex Sodium	79	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	79	64
Albuterol Sulfate Hfa	Albuterol Sulfate	78	41
Montelukast Sodium	Montelukast Sodium	78	suppressed
Ondansetron Hcl	Ondansetron Hcl	78	47
Ciprofloxacin Hcl	Ciprofloxacin Hcl	77	47
Diclofenac Sodium	Diclofenac Sodium	72	29
Entresto	Sacubitril/Valsartan	72	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	72	15
Metformin Hcl Er	Metformin Hcl	70	12
Brimonidine Tartrate	Brimonidine Tartrate	69	11
Ibuprofen	Ibuprofen	67	19
Oxybutynin Chloride Er	Oxybutynin Chloride	65	suppressed
Amiodarone Hcl	Amiodarone Hcl	64	12
Warfarin Sodium	Warfarin Sodium	62	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	61	43
Metolazone	Metolazone	61	13
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	60	suppressed
Nifedipine Er	Nifedipine	60	11
Baclofen	Baclofen	59	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	58	suppressed
Mupirocin	Mupirocin	58	30
Venlafaxine Hcl Er	Venlafaxine Hcl	56	suppressed
Aripiprazole	Aripiprazole	54	suppressed
Digoxin	Digoxin	54	suppressed
Santyl	Collagenase Clostridium Hist.	54	28
Tradjenta	Linagliptin	54	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	53	12
Celecoxib	Celecoxib	50	12
Lactulose	Lactulose	49	20
Tramadol Hcl	Tramadol Hcl	49	18
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	47	17
Humalog Kwikpen U-100	Insulin Lispro	47	12
Nystatin	Nystatin	46	16
Levofloxacin	Levofloxacin	45	32
Namzaric	Memantine Hcl/Donepezil Hcl	45	suppressed
Fenofibrate	Fenofibrate,micronized	43	suppressed
Paroxetine Hcl	Paroxetine Hcl	42	suppressed
Olanzapine	Olanzapine	41	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	40	19
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	40	36
Lacosamide	Lacosamide	39	suppressed
Trulicity	Dulaglutide	39	suppressed
Doxepin Hcl	Doxepin Hcl	38	suppressed
Combigan	Brimonidine Tartrate/Timolol	37	suppressed
Nitroglycerin	Nitroglycerin	37	18
Simvastatin	Simvastatin	37	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	36	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	36	suppressed
Ketoconazole	Ketoconazole	36	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	36	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	35	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	35	35
Anastrozole	Anastrozole	34	suppressed
Meclizine Hcl	Meclizine Hcl	34	suppressed
Memantine Hcl Er	Memantine Hcl	34	suppressed
Ranolazine Er	Ranolazine	34	suppressed
Ropinirole Hcl	Ropinirole Hcl	34	suppressed
Hydrocortisone	Hydrocortisone	31	suppressed
Amoxicillin	Amoxicillin	29	21
Dorzolamide Hcl	Dorzolamide Hcl	29	suppressed
Methotrexate	Methotrexate Sodium	29	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	29	suppressed
Ondansetron Odt	Ondansetron	29	23
Breo Ellipta	Fluticasone/Vilanterol	28	suppressed
Bupropion Xl	Bupropion Hcl	28	suppressed
Ceftriaxone	Ceftriaxone Sodium	28	22
Torsemide	Torsemide	28	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	28	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	27	suppressed
Linzess	Linaclotide	27	suppressed
Midodrine Hcl	Midodrine Hcl	27	11
Valproic Acid	Valproic Acid (As Sodium Salt)	27	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	26	suppressed
Lumigan	Bimatoprost	26	suppressed
Metronidazole	Metronidazole	26	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	18
Glipizide Er	Glipizide	25	suppressed
Lorazepam	Lorazepam	25	13
Naproxen	Naproxen	24	18
Oxcarbazepine	Oxcarbazepine	24	suppressed
Propranolol Hcl	Propranolol Hcl	24	suppressed
Alprazolam	Alprazolam	23	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	23	suppressed
Azelastine Hcl	Azelastine Hcl	23	11
Clonazepam	Clonazepam	23	suppressed
Lidocaine	Lidocaine	23	suppressed
Brilinta	Ticagrelor	22	suppressed
Felodipine Er	Felodipine	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Valsartan	Valsartan	22	suppressed
Galantamine Hbr	Galantamine Hbr	21	suppressed
Lidocaine Hcl	Lidocaine Hcl	21	18
Olmesartan Medoxomil	Olmesartan Medoxomil	21	suppressed
Phenytoin	Phenytoin	21	suppressed
Primidone	Primidone	21	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	20	suppressed
Vyzulta	Latanoprostene Bunod	20	suppressed
Calcitriol	Calcitriol	19	suppressed
Azithromycin	Azithromycin	18	17
Briviact	Brivaracetam	18	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	18	17
Tobramycin-Dexamethasone	Tobramycin/Dexamethasone	18	14
Bupropion Hcl	Bupropion Hcl	17	suppressed
Fluconazole	Fluconazole	17	11
Haloperidol	Haloperidol	17	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	17	suppressed
Methocarbamol	Methocarbamol	17	suppressed
Nebivolol Hcl	Nebivolol Hcl	17	suppressed
Sotalol	Sotalol Hcl	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Glipizide	Glipizide	16	suppressed
Ibandronate Sodium	Ibandronate Sodium	16	suppressed
Lagevrio (Eua)	Molnupiravir	16	16
Loperamide	Loperamide Hcl	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	13
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	15	suppressed
Farxiga	Dapagliflozin Propanediol	15	suppressed
Fluticasone-Vilanterol	Fluticasone/Vilanterol	15	suppressed
Levemir Flexpen	Insulin Detemir	15	suppressed
Lotemax	Loteprednol Etabonate	15	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	15	suppressed
Rivastigmine	Rivastigmine Tartrate	15	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	15	suppressed
Amantadine	Amantadine Hcl	14	suppressed
Cilostazol	Cilostazol	14	suppressed
Clonidine	Clonidine	14	suppressed
Insulin Aspart Flexpen	Insulin Aspart	14	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Novolin R Flexpen	Insulin Regular, Human	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Sodium Chloride	Sodium Chloride Irrig Solution	14	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	13	suppressed
Rhopressa	Netarsudil Mesylate	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Timolol Maleate	Timolol Maleate	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Mometasone Furoate	Mometasone Furoate	12	suppressed
Nystop	Nystatin	12	suppressed
Prednisolone Acetate	Prednisolone Acetate	12	suppressed
Ramipril	Ramipril	12	suppressed
Restasis	Cyclosporine	12	suppressed
Roflumilast	Roflumilast	12	suppressed
Tobramycin	Tobramycin	12	suppressed
Tresiba Flextouch U-200	Insulin Degludec	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Colchicine	Colchicine	11	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	11	suppressed
Invega Sustenna	Paliperidone Palmitate	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Rifampin	Rifampin	11	suppressed
Simbrinza	Brinzolamide/Brimonidine Tart	11	suppressed
Temazepam	Temazepam	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$27.76 · 2 records	AstraZeneca Pharmaceuticals LP	FARXIGA, NURTEC ODT, PAXLOVID	5	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error